These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 27117615)

  • 1. [Mechanisms of myeloma-induced bone disease].
    Abe M
    Clin Calcium; 2016 May; 26(5):699-706. PubMed ID: 27117615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Aug; 24(8):1159-68. PubMed ID: 25065867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Jun; 24(6):871-8. PubMed ID: 24870838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Myeloma bone disease and RANKL signaling].
    Abe M
    Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
    Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
    Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
    Abe M
    Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of osteocytes in multiple myeloma bone disease.
    Delgado-Calle J; Bellido T; Roodman GD
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):407-13. PubMed ID: 25289928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients.
    Zannettino AC; Farrugia AN; Kortesidis A; Manavis J; To LB; Martin SK; Diamond P; Tamamura H; Lapidot T; Fujii N; Gronthos S
    Cancer Res; 2005 Mar; 65(5):1700-9. PubMed ID: 15753365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.
    Giuliani N; Ferretti M; Bolzoni M; Storti P; Lazzaretti M; Dalla Palma B; Bonomini S; Martella E; Agnelli L; Neri A; Ceccarelli F; Palumbo C
    Leukemia; 2012 Jun; 26(6):1391-401. PubMed ID: 22289923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-host cell interactions in the bone disease of myeloma.
    Fowler JA; Edwards CM; Croucher PI
    Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Wnt signaling in myeloma.].
    Abe M
    Clin Calcium; 2019; 29(3):349-355. PubMed ID: 30814381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.
    Abe M
    Int J Hematol; 2011 Oct; 94(4):334-343. PubMed ID: 22005835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloma bone disease.
    Callander NS; Roodman GD
    Semin Hematol; 2001 Jul; 38(3):276-85. PubMed ID: 11486316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.
    Liu H; He J; Bagheri-Yarmand R; Li Z; Liu R; Wang Z; Bach DH; Huang YH; Lin P; Guise TA; Gagel RF; Yang J
    Nat Commun; 2022 Jun; 13(1):3684. PubMed ID: 35760800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New potential targets for treating myeloma bone disease.
    Roodman GD
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regulation of bone homeostasis by bone cells].
    Nakashima T
    Clin Calcium; 2013 Feb; 23(2):218-28. PubMed ID: 23354089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.